Skip to content Skip to sidebar Skip to footer

Newsletter

Biotech Stocks

The 50% CGT discount on shares: Here’s how it works, and if it is under threat

The 50% CGT discount on shares is one of the key mechanisms that helps investors keep as much of their cash as they have earned on their investments. We felt that it was time to write a stand-alone article about this in light of the inflation crisis and how it could lead to investors seeking…

ByNick SundichFebruary 5, 2026

PYC Therapeutics (ASX:PYC): Its been raising ~$650m to fund 4 clinical assets for multiple years!

PYC Therapeutics (ASX:PYC) is currently in the Top 25 ASX healthcare stocks and is the 4th largest biotech, only trailing Telix, Mesoblast and Neuren. Clearly this is one worth looking into and this was before a capital raising that would be $650m and purportedly fund the company into next decade. What are the Best ASX Life…

ByNick SundichFebruary 5, 2026

Epiminder (ASX:EPI): Less than 2 months since its IPO, this medtech made its first implant

Epiminder (ASX:EPI) only listed on the ASX at the end of November last year, but just announced to market that it completed the first implant of its Minder system in the USA. The company's Minder system is an epilepsy monitoring technology which is in a global clinical trial which will enrol over 200 patients. Shares only…

ByNick SundichJanuary 21, 2026

Neuren Pharmaceuticals (ASX:NEU) Surges 6% on US$700m DAYBUE Target: Time to Buy?

DAYBUE royalties could climb fast if US targets land Neuren Pharmaceuticals (ASX: NEU) jumped 6% on Wednesday after its US partner, Acadia Pharmaceuticals, shared big news at the J.P. Morgan Healthcare Conference. Acadia now expects DAYBUE sales to hit US$700 million by 2028, sending Neuren shares to around A$20.47. The stock has climbed more than…

ByUjjwal MaheshwariJanuary 15, 2026

NeuroScientific (ASX:NSB) Reports 75% Response Rate in Crohn’s Trial: Is This Stem Cell Stock a Buy?

NeuroScientific jumps on early Crohn’s stem cell results NeuroScientific Biopharmaceuticals (ASX: NSB) surged 43% on Tuesday after announcing promising early results from its stem cell program. Three out of four patients achieved a clinical response in a Special Access Program for fistulising Crohn's disease. The company's StemSmart therapy showed a 75% success rate in treating one…

ByUjjwal MaheshwariJanuary 14, 2026

Island Pharmaceuticals (ASX:ILA) Surges 12% on US Patent Win: Speculative Buy or Too Risky?

Island Pharmaceuticals Secures US Patent for Galidesivir Island Pharmaceuticals (ASX: ILA) jumped 12 per cent this week after announcing it secured a US patent for galidesivir, its antiviral drug designed to fight some of the world's deadliest viruses. While a broad US patent protects galidesivir’s use in COVID-19 until July 2042, the company just secured…

ByUjjwal MaheshwariJanuary 8, 2026

Ozempic and other GLP-1 Drugs: Here’s Where Things Are Headed in 2026

At Stocks Down Under, it has been a while since we've looked at Ozempic and other GLP-1 Drugs. Investors paid a lot of attention to them in 2023, particularly those invested in companies with potential to be impacted directly or indirectly. The industry has come a fair way in the past couple of years and…

ByNick SundichJanuary 6, 2026

Stocks Down Under’s Top 10 Hottest ASX Stocks to Look At in 2026!

Today, on the first trading day of 2026, Stocks Down Under publishes its its 10 Hottest ASX Stocks to Look At in the year ahead! What are the Best ASX Stocks to invest in right now? Check our buy/sell tips [sg_popup id="23914" event="click"][/sg_popup] Stocks Down Under's Top 10 Hottest ASX Stocks to Look At in 2026! Note: These…

ByNick SundichJanuary 2, 2026

Our 5 ASX Predictions for 2026!

This article outlines 5 ASX Predictions for 2026 that Stocks Down Under puts its neck on the line to assert will happen. It has become an annual tradition of ours, and some of these calls we get right, others we don't. Arguably our boldest call in suggesting ANZ would be the best performing big 4…

ByNick SundichDecember 24, 2025

Mesoblast (ASX:MSB) Reaches Multi-Year High as Ryoncil Revenue Targets US$30M: Is It Still a Buy?

Commercial momentum builds as Mesoblast targets two major 2026 catalysts: Adult label expansion and Revascor BLA filing. Mesoblast (ASX: MSB) closed at A$2.91 last Friday, up 27% over the past month as investors position ahead of the company's expected US$30 million-plus Q2 revenue report. The share price is now close to its January high of…

ByUjjwal MaheshwariDecember 22, 2025

the Kick-ass Multipurpose WordPress Theme

Biotech Stocks

The 50% CGT discount on shares: Here’s how it works, and if it is under threat

PYC Therapeutics (ASX:PYC): Its been raising ~$650m to fund 4 clinical assets for multiple years!

Epiminder (ASX:EPI): Less than 2 months since its IPO, this medtech made its first implant

Neuren Pharmaceuticals (ASX:NEU) Surges 6% on US$700m DAYBUE Target: Time to Buy?

NeuroScientific (ASX:NSB) Reports 75% Response Rate in Crohn’s Trial: Is This Stem Cell Stock a Buy?

Island Pharmaceuticals (ASX:ILA) Surges 12% on US Patent Win: Speculative Buy or Too Risky?

Ozempic and other GLP-1 Drugs: Here’s Where Things Are Headed in 2026

Stocks Down Under’s Top 10 Hottest ASX Stocks to Look At in 2026!

Our 5 ASX Predictions for 2026!

Mesoblast (ASX:MSB) Reaches Multi-Year High as Ryoncil Revenue Targets US$30M: Is It Still a Buy?

Investing in the Year of the Rat

2020, the Golden Year

Market trouble spots to avoid in 2020

Biotech Stocks

Add Your Heading Text Here